After analyzing the provided sources, I found that there is no direct comparison or statement regarding the preference of off-patent Tigecycline over generic versions. However, I can provide some context that might help explain this potential preference.

Tigecycline is an antibiotic used to treat various bacterial infections, and its patent expired in 2015 in the United States [1]. Post-patent expiration, generic versions of Tigecycline became available, leading to increased competition and potentially lower costs. Nevertheless, some factors might influence the preference for off-patent Tigecycline over generic alternatives:

1. Brand recognition and trust: Off-patent Tigecycline, previously marketed under the brand name Tygacil, might benefit from established brand recognition and trust among medical professionals [1][2].
2. Consistency in manufacturing and quality: Off-patent Tigecycline might offer greater consistency in manufacturing and quality control compared to various generic manufacturers [2].
3. Clinical experience and safety data: Off-patent Tigecycline might have a more extensive clinical experience and safety database, providing additional reassurance for prescribers [3].

It is essential to note that these factors do not necessarily imply that off-patent Tigecycline is inherently superior to generic alternatives. The choice between off-patent Tigecycline and generic versions should be based on individual patient needs, cost-effectiveness, and clinical judgment.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/TIGECYCLINE
[2] https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=SWD:2018:0240:FIN:EN:PDF
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378521/